Jnana Therapeutics’ Post

Phenylketonuria (PKU) is one of many rare genetic diseases that are diagnosed in childhood. There continues to be a critical need for a safe and efficacious treatment for PKU, which can cause progressive and severe neurological impairment and neuropsychological complications. At Jnana, we are currently advancing JNT-517 as a potential first-in-class oral treatment for PKU. Learn more about our clinical studies: https://bit.ly/41h4dUQ #RareDiseaseDay